CA2761068A1 - Nouveaux regimes posologiques et methodes de traitement, de prevention ou de gestion d'au moins un trouble du systeme nerveux central - Google Patents

Nouveaux regimes posologiques et methodes de traitement, de prevention ou de gestion d'au moins un trouble du systeme nerveux central Download PDF

Info

Publication number
CA2761068A1
CA2761068A1 CA 2761068 CA2761068A CA2761068A1 CA 2761068 A1 CA2761068 A1 CA 2761068A1 CA 2761068 CA2761068 CA 2761068 CA 2761068 A CA2761068 A CA 2761068A CA 2761068 A1 CA2761068 A1 CA 2761068A1
Authority
CA
Canada
Prior art keywords
lurasidone
compound
pharmaceutically acceptable
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2761068
Other languages
English (en)
Inventor
Antony D. Loebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CA2761068A1 publication Critical patent/CA2761068A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 2761068 2011-12-02 2011-12-07 Nouveaux regimes posologiques et methodes de traitement, de prevention ou de gestion d'au moins un trouble du systeme nerveux central Abandoned CA2761068A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566379P 2011-12-02 2011-12-02
US61/566,379 2011-12-02

Publications (1)

Publication Number Publication Date
CA2761068A1 true CA2761068A1 (fr) 2013-06-02

Family

ID=48570502

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2761068 Abandoned CA2761068A1 (fr) 2011-12-02 2011-12-07 Nouveaux regimes posologiques et methodes de traitement, de prevention ou de gestion d'au moins un trouble du systeme nerveux central

Country Status (1)

Country Link
CA (1) CA2761068A1 (fr)

Similar Documents

Publication Publication Date Title
Zhang et al. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia
Vena et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial
Meltzer et al. Pimavanserin, a selective serotonin (5-HT) 2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day
DK2892525T3 (en) METHODS OF TREATING MUSCLE DYROPHY
Miyamoto et al. Antipsychotic drugs
Kasper et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
DK2902035T3 (en) METHODS FOR TREATING MUSCLE DYROPHY
Berk et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial
Kelly et al. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations
JP2010116412A (ja) 精神分裂病を治療するための方法および組成物
US20180092909A1 (en) Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
EP2618826B1 (fr) Composés de phénylpipéridine pour le traitement de la demence
Jena et al. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial
JP2020075933A (ja) ストレス性疾患の予防および／または治療用医薬
Solas et al. 5-HT7 receptors in Alzheimer's disease
Chestnykh et al. Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure
Kennedy et al. A current review of olanzapine's safety in the geriatric patient: from pre‐clinical pharmacology to clinical data
Mozes et al. Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial
RU2675252C2 (ru) МОДУЛЯЦИЯ УРОВНЕЙ sAPP, sAPPα И BDNF У ИНДИВИДУУМОВ С ДИАГНОЗОМ FXS И ASD
Goto et al. Risperidone in the treatment of psychotic depression
Grauer et al. WAY-163909, a 5-HT 2C agonist, enhances the preclinical potency of current antipsychotics
Li et al. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens
Raskin et al. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder
Rosh et al. Synaptic dysfunction and dysregulation of extracellular matrix-related genes in dopaminergic neurons derived from Parkinson’s disease sporadic patients and with GBA1 mutations
CA2761068A1 (fr) Nouveaux regimes posologiques et methodes de traitement, de prevention ou de gestion d'au moins un trouble du systeme nerveux central

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161102

FZDE Dead

Effective date: 20190225